Breaking News Instant updates and real-time market news.

BLRX

BioLineRx

$1.44 /

-0.04 (-2.70%)

08:51
10/29/20
10/29
08:51
10/29/20
08:51

BioLineRx initiatesPhase 2 clinical trial in metastatic pancreatic cancer

BioLineRx's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the anti-PD-1 cemiplimab and standard-of-care chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma. This investigator-initiated Phase 2 study, led by Columbia University, will initially enroll 10-12 PDAC patients, and will be expanded to a total of 40 patients following an evaluation of the initial 10-12 patients based on pre-defined criteria. The primary endpoint of the study is the overall response rate. Secondary endpoints include safety and tolerability, progression free survival, duration of clinical benefit and overall survival. Data from the study is anticipated in mid-2022.

BLRX BioLineRx
$1.44 /

-0.04 (-2.70%)

03/13/20 Oppenheimer
BioLineRx price target lowered to $11 from $26 at Oppenheimer

TODAY'S FREE FLY STORIES

Earnings
Veeva reports Q3 adjusted EPS 78c, consensus 68c » 16:12
12/01/20
12/01
16:12
12/01/20
16:12
VEEV

Veeva

$284.82 /

+7.91 (+2.86%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$284.82 /

+7.91 (+2.86%)

VEEV Veeva
$284.82 /

+7.91 (+2.86%)

10/26/20 Raymond James
Veeva price target raised to $335 from $285 at Raymond James
10/13/20 UBS
Veeva initiated with a Sell at UBS
08/31/20 Morgan Stanley
Veeva price target raised to $323 from $253 at Morgan Stanley
08/28/20 FBN Securities
Veeva price target raised to $310 from $300 at FBN Securities
VEEV Veeva
$284.82 /

+7.91 (+2.86%)

VEEV Veeva
$284.82 /

+7.91 (+2.86%)

VEEV Veeva
$284.82 /

+7.91 (+2.86%)

Hot Stocks
Tredegar trading resumes  16:12
12/01/20
12/01
16:12
12/01/20
16:12
TG

Tredegar

$16.60 /

+0.85 (+5.40%)

 
ShowHide Related Items >><<
TG Tredegar
$16.60 /

+0.85 (+5.40%)

Hot Stocks
Blackbaud announces long-term goals » 16:12
12/01/20
12/01
16:12
12/01/20
16:12
BLKB

Blackbaud

$56.73 /

+1.71 (+3.11%)

"Over the long term,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BLKB Blackbaud
$56.73 /

+1.71 (+3.11%)

BLKB Blackbaud
$56.73 /

+1.71 (+3.11%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Stephens
Blackbaud initiated with an Overweight at Stephens
08/27/20 Stephens
Blackbaud initiated with an Overweight at Stephens
04/20/20 Evercore ISI
Blackbaud upgraded to In Line from Underperform at Evercore ISI
BLKB Blackbaud
$56.73 /

+1.71 (+3.11%)

BLKB Blackbaud
$56.73 /

+1.71 (+3.11%)

BLKB Blackbaud
$56.73 /

+1.71 (+3.11%)

Hot Stocks
Salesforce acquires Slack in cash and stock deal worth $27.7B » 16:12
12/01/20
12/01
16:12
12/01/20
16:12
WORK

Slack Technologies

$43.77 /

+0.88 (+2.05%)

, CRM

Salesforce

$241.70 /

-4.57 (-1.86%)

Salesforce (CRM) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WORK Slack Technologies
$43.77 /

+0.88 (+2.05%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.77 /

+0.88 (+2.05%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/30/20 Barclays
Slack Technologies downgraded to Equal Weight from Overweight at Barclays
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 MKM Partners
Facebook, Google may also be interested in Slack, says MKM Partners
CRM Salesforce
$241.70 /

-4.57 (-1.86%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
WORK Slack Technologies
$43.77 /

+0.88 (+2.05%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.77 /

+0.88 (+2.05%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.77 /

+0.88 (+2.05%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.77 /

+0.88 (+2.05%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

Hot Stocks
Arcutis Biotherapeutics presents data on roflumilast cream study for psoriasis » 16:12
12/01/20
12/01
16:12
12/01/20
16:12
ARQT

Arcutis Biotherapeutics

$25.05 /

-1.95 (-7.22%)

Arcutis Biotherapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

Syndicate
I-MAB files to sell 10.92M American depositary shares for holders  16:12
12/01/20
12/01
16:12
12/01/20
16:12
IMAB

I-MAB

$37.25 /

-1.5 (-3.87%)

 
ShowHide Related Items >><<
IMAB I-MAB
$37.25 /

-1.5 (-3.87%)

IMAB I-MAB
$37.25 /

-1.5 (-3.87%)

09/08/20 Cantor Fitzgerald
I-MAB price target raised to $55 from $50 at Cantor Fitzgerald
07/27/20 Cantor Fitzgerald
I-MAB initiated with an Overweight at Cantor Fitzgerald
02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
  • 17
    Jan
IMAB I-MAB
$37.25 /

-1.5 (-3.87%)

Earnings
ReneSola sees Q4 revenue $23M-$25M, consensus $33.31M » 16:12
12/01/20
12/01
16:12
12/01/20
16:12
SOL

ReneSola

$7.89 /

+ (+0.00%)

Q4 revenue outlook…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SOL ReneSola
$7.89 /

+ (+0.00%)

SOL ReneSola
$7.89 /

+ (+0.00%)

09/17/20 H.C. Wainwright
ReneSola initiated with a Buy at H.C. Wainwright
03/03/20
LD Micro to hold a virtual conference
SOL ReneSola
$7.89 /

+ (+0.00%)

SOL ReneSola
$7.89 /

+ (+0.00%)

Earnings
Salesforce sees Q4 EPS 73c-74c, consensus 86c  16:11
12/01/20
12/01
16:11
12/01/20
16:11
CRM

Salesforce

$241.66 /

-4.61 (-1.87%)

 
ShowHide Related Items >><<
CRM Salesforce
$241.66 /

-4.61 (-1.87%)

CRM Salesforce
$241.66 /

-4.61 (-1.87%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
CRM Salesforce
$241.66 /

-4.61 (-1.87%)

CRM Salesforce
$241.66 /

-4.61 (-1.87%)

CRM Salesforce
$241.66 /

-4.61 (-1.87%)

CRM Salesforce
$241.66 /

-4.61 (-1.87%)

Hot Stocks
Simulations Plus names Will Frederick CFO » 16:11
12/01/20
12/01
16:11
12/01/20
16:11
SLP

Simulations Plus

$56.59 /

+0.61 (+1.09%)

Simulations Plus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SLP Simulations Plus
$56.59 /

+0.61 (+1.09%)

SLP Simulations Plus
$56.59 /

+0.61 (+1.09%)

11/25/20 Taglich Brothers
Simulations Plus upgraded to Buy from Speculative Buy at Taglich Brothers
11/17/20 Craig-Hallum
Simulations Plus price target raised to $81 from $75 at Craig-Hallum
10/16/20 Raymond James
Simulations Plus initiated with an Outperform at Raymond James
10/16/20 Raymond James
Simulations Plus initiated with an Outperform at Raymond James
SLP Simulations Plus
$56.59 /

+0.61 (+1.09%)

  • 06
    Aug
SLP Simulations Plus
$56.59 /

+0.61 (+1.09%)

SLP Simulations Plus
$56.59 /

+0.61 (+1.09%)

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:11
12/01/20
12/01
16:11
12/01/20
16:11
CRM

Salesforce

$241.75 /

-4.52 (-1.84%)

Technology Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

Hot Stocks
Salesforce CFO MARK Hawkins to retire » 16:11
12/01/20
12/01
16:11
12/01/20
16:11
CRM

Salesforce

$241.75 /

-4.52 (-1.84%)

Salesforce announces that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

CRM Salesforce
$241.75 /

-4.52 (-1.84%)

Earnings
ReneSola reports Q3 non-GAAP EPS 5c, consensus 0c » 16:10
12/01/20
12/01
16:10
12/01/20
16:10
SOL

ReneSola

$7.90 /

+0.01 (+0.13%)

Reports Q3 revenue $9.7M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SOL ReneSola
$7.90 /

+0.01 (+0.13%)

SOL ReneSola
$7.90 /

+0.01 (+0.13%)

09/17/20 H.C. Wainwright
ReneSola initiated with a Buy at H.C. Wainwright
03/03/20
LD Micro to hold a virtual conference
SOL ReneSola
$7.90 /

+0.01 (+0.13%)

Earnings
Cohu sees Q4 revenue $195M-$200M, consensus $186.26M » 16:10
12/01/20
12/01
16:10
12/01/20
16:10
COHU

Cohu

$29.70 /

+1.36 (+4.80%)

Luis Mueller, President…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COHU Cohu
$29.70 /

+1.36 (+4.80%)

11/30/20 B. Riley Securities
Cohu price target raised to $40 from $37 at B. Riley Securities
11/12/20 DA Davidson
Cohu price target raised to $33 from $25 at DA Davidson
11/12/20 Deutsche Bank
Cohu price target raised to $28 from $24 at Deutsche Bank
10/30/20 Deutsche Bank
Cohu price target raised to $220 from $205 at Deutsche Bank
COHU Cohu
$29.70 /

+1.36 (+4.80%)

COHU Cohu
$29.70 /

+1.36 (+4.80%)

Syndicate
Update: Twist Bioscience files to sell $250M in common stock » 16:10
12/01/20
12/01
16:10
12/01/20
16:10
TWST

Twist Bioscience

$118.29 /

+6.06 (+5.40%)

Twist Bioscience…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TWST Twist Bioscience
$118.29 /

+6.06 (+5.40%)

TWST Twist Bioscience
$118.29 /

+6.06 (+5.40%)

11/24/20 SVB Leerink
Twist Bioscience price target raised to $100 from $90 at SVB Leerink
11/24/20 Baird
Twist Bioscience price target raised to $125 from $70 at Baird
10/20/20 SVB Leerink
Twist Bioscience initiated with a Market Perform at SVB Leerink
02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
TWST Twist Bioscience
$118.29 /

+6.06 (+5.40%)

  • 03
    Dec
  • 04
    Jun
  • 20
    Feb
TWST Twist Bioscience
$118.29 /

+6.06 (+5.40%)

Earnings
Salesforce sees Q4 revenue $5.665B-$5.675B, consensus $5.52B  16:09
12/01/20
12/01
16:09
12/01/20
16:09
CRM

Salesforce

$241.70 /

-4.57 (-1.86%)

 
ShowHide Related Items >><<
CRM Salesforce
$241.70 /

-4.57 (-1.86%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
CRM Salesforce
$241.70 /

-4.57 (-1.86%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

Hot Stocks
Salesforce to acquire Slack in cash and stock deal worth $27.7B » 16:09
12/01/20
12/01
16:09
12/01/20
16:09
WORK

Slack Technologies

$43.94 /

+1.05 (+2.45%)

, CRM

Salesforce

$241.70 /

-4.57 (-1.86%)

Under the terms of the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WORK Slack Technologies
$43.94 /

+1.05 (+2.45%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.94 /

+1.05 (+2.45%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/30/20 Barclays
Slack Technologies downgraded to Equal Weight from Overweight at Barclays
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 MKM Partners
Facebook, Google may also be interested in Slack, says MKM Partners
CRM Salesforce
$241.70 /

-4.57 (-1.86%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
WORK Slack Technologies
$43.94 /

+1.05 (+2.45%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.94 /

+1.05 (+2.45%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.94 /

+1.05 (+2.45%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

WORK Slack Technologies
$43.94 /

+1.05 (+2.45%)

CRM Salesforce
$241.70 /

-4.57 (-1.86%)

Earnings
Inter Parfums sees FY21 EPS $1.20-$1.25, consensus $1.62 » 16:09
12/01/20
12/01
16:09
12/01/20
16:09
IPAR

Inter Parfums

$55.75 /

+1.37 (+2.52%)

Sees FY21 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IPAR Inter Parfums
$55.75 /

+1.37 (+2.52%)

IPAR Inter Parfums
$55.75 /

+1.37 (+2.52%)

11/11/20 DA Davidson
Inter Parfums price target raised to $55 from $39 at DA Davidson
11/11/20 Citi
Inter Parfums price target raised to $56 from $46 at Citi
08/12/20 BWS Financial
Inter Parfums upgraded to Buy from Neutral at BWS Financial
06/12/20 DA Davidson
Inter Parfums price target raised to $41 from $36 at DA Davidson
IPAR Inter Parfums
$55.75 /

+1.37 (+2.52%)

IPAR Inter Parfums
$55.75 /

+1.37 (+2.52%)

Earnings
Salesforce reports Q3 EPS $1.74, consensus 75c » 16:09
12/01/20
12/01
16:09
12/01/20
16:09
CRM

Salesforce

$241.69 /

-4.58 (-1.86%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$241.69 /

-4.58 (-1.86%)

CRM Salesforce
$241.69 /

-4.58 (-1.86%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
CRM Salesforce
$241.69 /

-4.58 (-1.86%)

CRM Salesforce
$241.69 /

-4.58 (-1.86%)

CRM Salesforce
$241.69 /

-4.58 (-1.86%)

CRM Salesforce
$241.69 /

-4.58 (-1.86%)

Hot Stocks
XpresSpa names David Kohel as its CTO » 16:07
12/01/20
12/01
16:07
12/01/20
16:07
XSPA

XpresSpa

$1.50 /

-0.14 (-8.54%)

XpresSpa announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XSPA XpresSpa
$1.50 /

-0.14 (-8.54%)

XSPA XpresSpa
$1.50 /

-0.14 (-8.54%)

XSPA XpresSpa
$1.50 /

-0.14 (-8.54%)

XSPA XpresSpa
$1.50 /

-0.14 (-8.54%)

Earnings
HP Enterprise sees FY21 adjusted EPS $1.60-$1.78, consensus $1.54 » 16:07
12/01/20
12/01
16:07
12/01/20
16:07
HPE

HP Enterprise

$11.29 /

+0.26 (+2.36%)

Fiscal 2021 non-GAAP…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HPE HP Enterprise
$11.29 /

+0.26 (+2.36%)

HPE HP Enterprise
$11.29 /

+0.26 (+2.36%)

11/16/20
Fly Intel: Top five analyst upgrades
11/16/20 Raymond James
HP Enterprise upgraded to Outperform from Market Perform at Raymond James
11/16/20 Raymond James
HP Enterprise upgraded to Outperform from Market Perform at Raymond James
09/22/20 UBS
HP Enterprise assumed with a Neutral at UBS
HPE HP Enterprise
$11.29 /

+0.26 (+2.36%)

HPE HP Enterprise
$11.29 /

+0.26 (+2.36%)

HPE HP Enterprise
$11.29 /

+0.26 (+2.36%)

HPE HP Enterprise
$11.29 /

+0.26 (+2.36%)

Hot Stocks
Galapagos announces 1st dosing in Mangrove trial in GLPG2737 with ADPKD patient » 16:07
12/01/20
12/01
16:07
12/01/20
16:07
GLPG

Galapagos

$127.36 /

+4.56 (+3.71%)

Galapagos NV announces…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GLPG Galapagos
$127.36 /

+4.56 (+3.71%)

GLPG Galapagos
$127.36 /

+4.56 (+3.71%)

11/23/20 UBS
Galapagos price target lowered to EUR 116 from EUR 125 at UBS
11/19/20 Maxim
Galapagos initiated with a Buy at Maxim
11/12/20 JPMorgan
Galapagos price target lowered to EUR 120 from EUR 130 at JPMorgan
11/12/20 JPMorgan
Galapagos price target lowered to $142 from $152 at JPMorgan
GLPG Galapagos
$127.36 /

+4.56 (+3.71%)

GLPG Galapagos
$127.36 /

+4.56 (+3.71%)

Hot Stocks
Salesforce to acquire Slack in cash and stock for enterprise value of $27.7B » 16:07
12/01/20
12/01
16:07
12/01/20
16:07
CRM

Salesforce

$241.67 /

-4.6 (-1.87%)

Salesforce (CRM) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$241.67 /

-4.6 (-1.87%)

CRM Salesforce
$241.67 /

-4.6 (-1.87%)

11/30/20 Barclays
Barclays sees limited upside for Slack after rally, downgrades shares
11/27/20 Morgan Stanley
Salesforce deal for Slack would likely be dilutive, says Morgan Stanley
11/27/20 DA Davidson
Salesforce acquisition of Slack would 'make sense', says DA Davidson
11/27/20 Needham
Needham 'not enamored' with potential Salesforce acquisition of Slack
CRM Salesforce
$241.67 /

-4.6 (-1.87%)

CRM Salesforce
$241.67 /

-4.6 (-1.87%)

CRM Salesforce
$241.67 /

-4.6 (-1.87%)

CRM Salesforce
$241.67 /

-4.6 (-1.87%)

Recommendations
Agios' success 'bodes well' for ACTIVATE-T trial, says Oppenheimer » 16:07
12/01/20
12/01
16:07
12/01/20
16:07
AGIO

Agios Pharmaceuticals

$46.58 /

+0.27 (+0.58%)

After Agios announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$46.58 /

+0.27 (+0.58%)

AGIO Agios Pharmaceuticals
$46.58 /

+0.27 (+0.58%)

11/20/20 Barclays
Agios Pharmaceuticals price target raised to $50 from $46 at Barclays
11/19/20 Piper Sandler
Piper continues to like setup for Agios Pharmaceuticals shares into ASH
11/19/20 Cantor Fitzgerald
Agios Pharmaceuticals price target raised to $79 from $68 at Cantor Fitzgerald
10/22/20 Barclays
Agios upgraded to Overweight with $46 target at Barclays
AGIO Agios Pharmaceuticals
$46.58 /

+0.27 (+0.58%)

AGIO Agios Pharmaceuticals
$46.58 /

+0.27 (+0.58%)

Earnings
HP Enterprise sees Q1 adjusted EPS 40c-44c, consensus 35c » 16:06
12/01/20
12/01
16:06
12/01/20
16:06
HPE

HP Enterprise

$11.27 /

+0.235 (+2.13%)

Fiscal 2021 first quarter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HPE HP Enterprise
$11.27 /

+0.235 (+2.13%)

HPE HP Enterprise
$11.27 /

+0.235 (+2.13%)

11/16/20
Fly Intel: Top five analyst upgrades
11/16/20 Raymond James
HP Enterprise upgraded to Outperform from Market Perform at Raymond James
11/16/20 Raymond James
HP Enterprise upgraded to Outperform from Market Perform at Raymond James
09/22/20 UBS
HP Enterprise assumed with a Neutral at UBS
HPE HP Enterprise
$11.27 /

+0.235 (+2.13%)

HPE HP Enterprise
$11.27 /

+0.235 (+2.13%)

HPE HP Enterprise
$11.27 /

+0.235 (+2.13%)

HPE HP Enterprise
$11.27 /

+0.235 (+2.13%)

Hot Stocks
Agree Realty raises dividend 6% to 62c » 16:06
12/01/20
12/01
16:06
12/01/20
16:06
ADC

Agree Realty

$66.29 /

+0.39 (+0.59%)

The Board of Directors…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADC Agree Realty
$66.29 /

+0.39 (+0.59%)

ADC Agree Realty
$66.29 /

+0.39 (+0.59%)

10/12/20 BTIG
Agree Realty initiated with a Buy at BTIG
09/29/20 Mizuho
Agree Realty initiated with a Buy at Mizuho
07/02/20 Citi
Agree Realty price target raised to $76 from $70 at Citi
06/10/20 Wells Fargo
Agree Realty price target raised to $75 from $67 at Wells Fargo
ADC Agree Realty
$66.29 /

+0.39 (+0.59%)

  • 31
    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.